66 related articles for article (PubMed ID: 11781647)
21. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy.
Sportès C; Babb RR; Krumlauf MC; Hakim FT; Steinberg SM; Chow CK; Brown MR; Fleisher TA; Noel P; Maric I; Stetler-Stevenson M; Engel J; Buffet R; Morre M; Amato RJ; Pecora A; Mackall CL; Gress RE
Clin Cancer Res; 2010 Jan; 16(2):727-35. PubMed ID: 20068111
[TBL] [Abstract][Full Text] [Related]
22. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma.
Venstrom JM; Zheng J; Noor N; Danis KE; Yeh AW; Cheung IY; Dupont B; O'Reilly RJ; Cheung NK; Hsu KC
Clin Cancer Res; 2009 Dec; 15(23):7330-4. PubMed ID: 19934297
[TBL] [Abstract][Full Text] [Related]
23. Significant impairment in immune recovery after cancer treatment.
Kang DH; Weaver MT; Park NJ; Smith B; McArdle T; Carpenter J
Nurs Res; 2009; 58(2):105-14. PubMed ID: 19289931
[TBL] [Abstract][Full Text] [Related]
24. Post-transplant adoptive T-cell immunotherapy.
Aqui NA; June CH
Best Pract Res Clin Haematol; 2008 Sep; 21(3):503-19. PubMed ID: 18790452
[TBL] [Abstract][Full Text] [Related]
25. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study.
Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Gastineau DA; Litzow MR; Winters JL; Markovic SN
Biol Blood Marrow Transplant; 2008 Jul; 14(7):807-16. PubMed ID: 18541201
[TBL] [Abstract][Full Text] [Related]
26. Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors.
Zakrzewski JL; Suh D; Markley JC; Smith OM; King C; Goldberg GL; Jenq R; Holland AM; Grubin J; Cabrera-Perez J; Brentjens RJ; Lu SX; Rizzuto G; Sant'Angelo DB; Riviere I; Sadelain M; Heller G; Zúñiga-Pflücker JC; Lu C; van den Brink MR
Nat Biotechnol; 2008 Apr; 26(4):453-61. PubMed ID: 18376399
[TBL] [Abstract][Full Text] [Related]
27. Immune reconstitution prevents metastatic recurrence of murine osteosarcoma.
Merchant MS; Melchionda F; Sinha M; Khanna C; Helman L; Mackall CL
Cancer Immunol Immunother; 2007 Jul; 56(7):1037-46. PubMed ID: 17149595
[TBL] [Abstract][Full Text] [Related]
28. Stem-cell transplantation for the treatment of advanced solid tumors.
Nieto Y; Jones RB; Shpall EJ
Springer Semin Immunopathol; 2004 Nov; 26(1-2):31-56. PubMed ID: 15368078
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of high-dose chemotherapy and autologous stem cell transplant in isolated locally recurrent breast cancer: a multicenter evaluation.
Vij R; DiPersio J; Brown R; Trinkaus K; Abboud C; Meehan KR; Frenette G; Freytes C; Goodnough LT; Khoury H; Ponnuri J; Adkins D
Bone Marrow Transplant; 2000 Nov; 26(9):947-53. PubMed ID: 11100273
[TBL] [Abstract][Full Text] [Related]
30. The sound and the fury: an update on the role of high-dose chemotherapy and autologous stem cell salvage for both metastatic and high-risk breast cancer.
Bar MH
Conn Med; 2000 Jan; 64(1):3-6. PubMed ID: 10697358
[No Abstract] [Full Text] [Related]
31. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer.
Porrata LF; Ingle JN; Litzow MR; Geyer S; Markovic SN
Bone Marrow Transplant; 2001 Nov; 28(9):865-71. PubMed ID: 11781647
[TBL] [Abstract][Full Text] [Related]
32. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis.
Porrata LF; Gertz MA; Litzow MR; Lacy MQ; Dispenzieri A; Inwards DJ; Ansell SM; Micallef IN; Gastineau DA; Elliott M; Hogan WJ; Hayman SR; Tefferi A; Markovic SN
Clin Cancer Res; 2005 Feb; 11(3):1210-8. PubMed ID: 15709191
[TBL] [Abstract][Full Text] [Related]
33. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma.
Joao C; Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Gastineau DA; Markovic SN
Bone Marrow Transplant; 2006 May; 37(9):865-71. PubMed ID: 16532015
[TBL] [Abstract][Full Text] [Related]
34. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
35. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.
Yoon DH; Sohn BS; Jang G; Kim EK; Kang BW; Kim C; Kim JE; Kim S; Lee DH; Lee JS; Park SJ; Park CJ; Huh J; Suh C
Transfusion; 2009 Sep; 49(9):1890-900. PubMed ID: 19453991
[TBL] [Abstract][Full Text] [Related]
36. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma.
Porrata LF; Litzow MR; Inwards DJ; Gastineau DA; Moore SB; Pineda AA; Bundy KL; Padley DJ; Persky D; Ansell SM; Micallef IN; Markovic SN
Bone Marrow Transplant; 2004 Feb; 33(3):291-8. PubMed ID: 14676784
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
